New hope for tough colon cancer: Drug-Radiation combo trial launched
NCT ID NCT06603818
First seen Feb 20, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tested two immunotherapy drugs (tiragolumab and atezolizumab) plus targeted radiation for people with a type of advanced colorectal cancer called microsatellite stable (MSS) that doesn't respond well to standard immunotherapy. The trial aimed to find the right dose and see if the combination could stop cancer growth for at least 9 weeks. It was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.